# Neoadjuvant Chemotherapy for Operable Premenopausal Breast Cancer Patients

> **NCT01503905** · NA · UNKNOWN · sponsor: **Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University** · enrollment: 600 (estimated)

## Conditions studied

- Breast Cancer Nos Premenopausal

## Interventions

- **DRUG:** Docetaxel
- **DRUG:** epirubicin
- **DRUG:** cyclophosphamide
- **PROCEDURE:** Modified radical mastectomy or breast-conserving Surgery
- **DRUG:** Docetaxel (post-operative)
- **DRUG:** Epirubicin (post-operative)
- **DRUG:** Cyclophosphamide (post-operative)
- **RADIATION:** Radiation therapy
- **DRUG:** Herceptin （post-operative)
- **DRUG:** Tamoxifen (post-operative)

## Key facts

- **NCT ID:** NCT01503905
- **Lead sponsor:** Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2011-12
- **Primary completion:** 2018-05
- **Final completion:** 2021-12
- **Target enrollment:** 600 (ESTIMATED)
- **Last updated:** 2016-05-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01503905

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01503905, "Neoadjuvant Chemotherapy for Operable Premenopausal Breast Cancer Patients". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT01503905. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*